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Abstract
Background/Aims—Patients with chronic kidney disease mineral and bone disorder (CKD-
MBD) have a significantly higher vertebral and non-vertebral fracture risk than the general 
population. Several preclinical models have documented altered skeletal properties in long bones, 
but few data exist for vertebral bone. The goal of this study was to examine the effects of 
progressive CKD on vertebral bone structure and mechanics and to determine the effects of 
treatment with either bisphosphonates or anti-sclerostin antibody in groups of animals with high or 
low PTH.
Methods—Animals with progressive kidney disease were left untreated, treated with calcium to 
lower PTH, zoledronic acid to lower remodeling without affecting PTH, anti-sclerostin antibody, 
or anti-sclerostin antibody plus calcium. Non-diseased, untreated littermates served as controls. 
Vertebral bone morphology (trabecular and cortical) and mechanical properties (structural and 
material-level) were assessed at 35 weeks of age by microCT and mechanical testing, respectively.
Results—CKD with high PTH resulted in 6-fold higher bone formation rate, significant 
reductions in the amount of trabecular and cortical bone, and compromised whole bone 
mechanical properties in the vertebra compared to normal animals. Treatments that reduced bone 
remodeling were effective in normalizing vertebral structure and mechanical properties only if the 
treatment reduced serum PTH. Similarly, treatment with anti-sclerostin antibody was effective in 
enhancing bone mass and mechanical properties but only if combined with PTH-suppressive 
treatment.
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Conclusions—CKD significantly altered both cortical and trabecular bone properties in the 
vertebra resulting in compromised mechanical properties and these changes can be normalized by 
interventions that involve reductions in PTH levels.
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INTRODUCTION
Patients with chronic kidney disease—mineral and bone disorder (CKD-MBD) have a 
significantly higher fracture risk than the general population [1-3]. This population also 
displays differences in fracture rates between long bones and vertebrae [3], suggesting that 
these two skeletal sites may be differentially affected by the disease. A study of Japanese 
men on dialysis who underwent screening lumbar spine imaging studies demonstrated that 
20.9% of prevalent dialysis patients had evidence of spine fractures [4]. High resolution CT 
data have revealed significant increases in cortical porosity in the distal limbs with variable 
responses in trabecular bone [5]. Because vertebral elements are primarily composed of 
trabecular bone, the influence of secondary hyperparathyroidism on these sites could be 
potentially different than in long bone cortices [6]. Furthermore, the thin cortical shell of the 
vertebrae bears nearly 50% of the load [7]; thus, cortical bone changes at this site would also 
have dramatic effects on mechanical properties and fracture risk
Several animal models of CKD have revealed significant detriments in the biomechanical 
properties of long bones [8-10]. For example, rodent models indicate that animals with CKD 
exhibit lower strength and stiffness compared to their normal counterparts [11-13]. While 
much of the decline in mechanical integrity can be attributed to structural changes resulting 
from high parathyroid hormone (PTH) and high turnover rates, recent studies indicate that 
bone quality also plays a role [9]. Unfortunately, vertebral bone in CKD models has yet to 
be examined at any of these levels. The goal of this study was to assess the effects of 
progressive CKD on vertebral bone structure and mechanics and to determine the effects of 
treatment with either anti-remodeling medications (bisphosphonates) or anabolic treatments 
(anti-sclerostin antibody). We hypothesized that a significant phenotype would exist in the 
vertebrae of CKD animals and that treatment would restore structural mechanical properties 
but not the material-level mechanical properties.
METHODS
Animal model
Cy/+ rats exhibit the progressive onset of polycystic kidney disease due to transmission of 
an autosomal dominant missense mutation in the geneAnks6, which codes for the protein 
SamCystin [14-16]. Anks6 has been shown to be important in childhood recessive cystic 
kidney disease although heterozygote parents have no manifestations [17-19]. The course of 
kidney disease progression in the Cy/+ rats parallels the course of human CKD-Mineral 
Bone Disorder (CKD-MBD) [16]. A colony of these animals is maintained at the Indiana 
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University School of Medicine. All procedures were reviewed and approved by the Indiana 
University School of Medicine Institutional Animal Care and Use Committee.
Experimental design
The animals described in this work were part of a large experiment that included numerous 
treatment and control groups. Male Cy/+ rats began the study at 25 weeks of age at which 
time animals were fed a casein-based diet (Purina AIN-76A, Purina Animal Nutrition, 
Shreevport, LA, USA); 0.53% Ca and 0.56% P) in order to accentuate the disease. Subsets 
of Cy/+ animals were divided into the following groups (Figure 1):
Controls (CKD)—These animals were left untreated. Based on the previously described 
phenotype these animals have high PTH and high bone turnover [11,20].
Calcium (CKD-Ca)—These animals were treated with calcium-supplemented water (3%) 
starting at 30 weeks of age. Based on the previously described phenotype these animals have 
low PTH and low bone turnover [11,20].
Zoledronic acid (CKD-Z)—These animals were treated with zoledronic acid (20 
ug/kg/BW as a single subcutaneous injection at 30 weeks of age). Based on the previously 
described phenotype these animals have high PTH and low bone turnover [11,20]. 
Zoledronic acid was chosen as a representative bisphosphonate to study in CKD as it has an 
infrequent dosing schedule (1x per year in post-menopausal osteoporosis treatment) and has 
high affinity for the bone matrix thus likely to impart persistent treatment effects.
Anti-sclerostin antibody (CKD-SCL)—These animals were treated with anti-sclerostin 
antibody (Scl-Ab; 100 mg/kg/week starting at 30 weeks of age). Scl-AB was provided by 
Novartis Institutes for BioMedical Research, Novartis Pharma AG. Based on the previously 
described phenotype these animals have high PTH and high bone turnover [11,20]. Anti-
sclerostin antibody was chosen as it has emerged as a promising potential anabolic drug 
treatment.
Anti-sclerostin antibody plus calcium (CKD-SCL-Ca): These animals were treated with 
anti-sclerostin antibody and calcium (3% in water). Based on the previously described 
phenotype these animals have low PTH and high bone turnover [11,20].
Normal (NL)—A group of non-diseased male littermates were untreated.
All animals were sacrificed at 35 weeks of age. For all experiments, serum biochemistries 
and long bone phenotypes have been previously reported in various publications, yet are 
repeated in the results when deemed necessary [11,13,20].
Dynamic Histomorphometry
In order to describe the basal remodeling phenotype of the vertebra in NL and CKD animals, 
the third lumbar vertebra of animals from a separate experiment [13] was processed for 
undecalcified histomorphometry. The vertebral arch was removed, and the body was 
embedded in PMMA for sectioning. Thin sections (~4 um) were cut and left unstained for 
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analysis. Briefly, a 2 mm2 region of interest in the caudal region of the vertebra cranial to 
the growth plate was used for the analysis. Primary measurements were obtained and used 
for the derived parameters mineralizing surface/bone surface (MS/BS), mineral apposition 
rate (MAR), and bone formation rate/bone surface (BFR) as previously described [11] using 
standard nomenclature [21].
Computed tomography
Morphological parameters of the fourth lumbar vertebrae from all experiments were 
assessed using high-resolution micro-CT (Skyscan 1172). Bones were wrapped in parafilm 
to prevent drying during the scanning. Scans were obtained using an x-ray source, set at 
60kV with a 12-μm pixel size.
Images were reconstructed and analyzed using standard Skyscan software (NRecon and 
CTAn, respectively). Trabecular regions of interest were manually drawn to isolate it from 
the cortical bone between the cranial and caudal growth plates. Bone volume/tissue volume 
(BV/TV), trabecular number (Tb.N), and trabecular thickness (Tb.Th) were computed 
according to previously published recommendations [22]. A single slice at 75% of the total 
vertebral length (from cranial to caudal) was used for the assessment of cortical thickness as 
this represents a region devoid of zygapophyseal attachment. Bone area was assessed at 
25%, 50%, and 75% of the total height for normalization of mechanical properties.
Mechanics
Structural mechanical properties and apparent material properties were assessed by uniaxial 
compression testing of the L4 vertebra from all 3 experiments. At harvest, the vertebrae 
were wrapped in saline-soaked gauze and frozen at -20 degrees. Bone height was assessed 
from microCT images. Prior to mechanical testing, the vertebral arch and the endplates were 
removed using an Isomet saw in order to create parallel surfaces (beneath the growth plates) 
for compression testing. Samples were loaded in displacement control at 0.5 mm/min. Load 
and displacement data were collected at 10 Hz and converted to stress and strain data from 
the initial sample height and the average bone area of 3 slices (25%, 50%, and 75% slices of 
the initial height of the sample). Load-displacement data were used to compute ultimate 
load, stiffness, and energy to failure (with failure defined as the point ultimate load first 
drops off), while apparent material properties were derived from the stress-strain data and 
used to calculate ultimate stress, elastic modulus, and toughness to the point of the ultimate 
stress [23].
Statistics
Statistics were carried out on select groups in order to answer a priori questions related to 1) 
basal phenotype of the CKD model, 2) the effects of anti-remodeling treatment with and 
without altered PTH levels, and 3) the effects of anabolic treatment with and without altered 
PTH levels (Figure 1). Comparisons were made using student's t-tests or one-way ANOVA 
followed by Fisher protected least significant difference post hoc tests. P values were set at 
< 0.05. Data are reported as means and standard deviations.
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RESULTS
CKD with high PTH leads to high remodeling rate, bone loss, and compromised structural 
and material mechanical properties
Select biochemistries and animal body weights are presented in Table 1. PTH levels in the 
CKD animals were over 10-fold higher than normal animals (Figure 1). Histological 
assessment of vertebral trabecular bone revealed that mineral apposition rate was more than 
doubled (NL = 1.21.; CKD = 2.98), mineralizing surface/bone surface was 2.5x higher (NL 
= 10.5; CKD = 24.5) and bone formation was 6-fold higher in CKD animals compared to 
normal (Figure 2A). Thus, the untreated CKD model is one of high PTH and high 
remodeling as illustrated in the photomicrographs (Figure 2F-G).
Vertebral microCT analyses showed that cortical thickness (−17%) and trabecular BV/TV 
(−30%) were both significantly lower in CKD compared to normal (Figure 2B&C and H-
K; Table 2). Ultimate force (−34%), stiffness (−21%), and energy to failure (−42%) were 
all significantly lower in CKD compared to NL (Figure 2D &E; Table 2). Calculation of 
material properties revealed significant lower ultimate stress (−24%) and toughness (−34%), 
but not modulus, in CKD animals (Table 2).
Low turnover with suppression of PTH normalizes vertebral bone morphology and 
mechanical properties
CKD animals treated with calcium (CKD-Ca), which reduced PTH and tibial bone 
suppresses bone remodeling [20], had similar vertebral cortical thickness but significantly 
higher trabecular BV/TV (+15%), compared to normal, non-diseased animals (Figure 
3A&B; Table 2). Cortical thickness and BV/TV in CKD-Ca were both significantly higher 
than CKD animals. Ultimate load and energy to failure of CKD-Ca vertrebrae were 
equivalent to NL (and higher than CKD) with the exception of stiffness, which was not 
significantly different among groups (Figure 3C&D; Table 2). Ultimate stress, modulus, 
and toughness of CKD-Ca were all equal or higher than NL animals (Table 2) and all higher 
than CKD.
In animals treated with zoledronic acid (CKD-Z), which suppresses bone remodeling 
without lowering PTH [20], the results were in stark contrast to CKD-Ca. Cortical thickness 
(−16%) and trabecular BV/TV (−18%) were both significantly lower than NL and CKD-Ca 
(Figure 3A&B; Table 2). Ultimate force (−28%) was significantly lower in CKD-Z 
compared to NL, while stiffness and energy to failure were not different (Figure 3C&D; 
Table 2). Ultimate stress and modulus were lower than NL, while all three material 
properties were significantly lower than CKD-Ca (Table 2).
High turnover with suppression of PTH, but not without, enhances vertebral morphology 
and vertebral mechanical properties
CKD animals with high PTH treated with anti-sclerostin antibody, previously shown to not 
alter PTH or bone remodeling relative to untreated CKD [20], had significantly lower 
cortical thickness (−11%), trabecular bone volume (−27%), and ultimate load (−32%), and 
stiffness (−54%) compared to NL (Figure 4A-C; Table 2). Ultimate stress and modulus 
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were both significantly lower than NL (Table 2). Overall, the vertebral phenotype of the 
CKD-Scl animals closely resembled the CKD animals with the exception of stiffness/
modulus (which were lower) and energy to failure/toughness (which were higher).
When anti-sclerostin antibody was combined with calcium (CKD-SCL-Ca), effectively 
reducing PTH and normalizing remodeling to NL levels [20], the results were dramatically 
different than anti-sclerostin alone. Cortical thickness was equivalent to NL animals while 
BV/TV (+15%) was significantly higher than NL, equivalent to CKD-Ca (Figure 4A&B; 
Table 2). Ultimate load (+25%) was significantly higher than all other treatments while 
energy to failure (+51%) was significantly higher than all treatments except CKD-Ca 
(Figure 4C&D; Table 2) while material properties were all comparable to NL animals, 
higher than most other groups (Table 2).
DISCUSSION
The goal of this study was to assess the vertebral phenotype of CKD given the high clinical 
risk of vertebral fracture in this patient population [4,24] and the paucity of preclinical data 
on spine changes with CKD. In this progressive CKD animal model we found 1) elevations 
in endogenous PTH were associated with high turnover bone disease, compromised cortical 
and trabecular bone mass, and reduced mechanical properties (both structural and material) 
of the vertebra and 2) treatment of the vertebral phenotype with either anti-resorptive or 
anabolic therapies was only effective, from a mechanical standpoint, if serum PTH was 
reduced.
CKD patients have a higher risk of fracture compared to non-CKD patients [25]. Changes to 
long bones have been the central focus of most clinical work due to the advances in high-
resolution peripheral imaging which has yielded rich information regarding changes to 
cortical/trabecular bone. Most notably these studies have shown that changes to the cortical 
bone are dramatic [5] and more severe than are typically observed with post-menopausal 
osteoporosis (which affects trabecular bone to a greater degree, at least initially). The risk of 
vertebral fracture is also increased in CKD patients [4,24,26,27], yet little information exists 
regarding changes to bone mass/architecture at this site. The distribution of cortical and 
trabecular bone in the vertebra differs significantly from long bones and although cortical 
bone still contributes to the mechanical integrity of the spine [7], it is possible that the 
intricacies of bone loss may differ from long bones. The paucity of clinical studies focused 
on the spine is understandable due to imaging limitations. However for reasons that are 
unclear this extends to preclinical studies where few studies have examined vertebral bone 
[8].
The current study showed dramatic loss of trabecular bone mass and thinning of the cortical 
shell in the vertebra of CKD animals with high PTH, irrespective of whether they were 
untreated, treated with bisphosphonate, or treated with anti-sclerostin antibody. These results 
contrast with the long bone phenotype of these same animals where cortical porosity was 
higher than normal but trabecular BV/TV was not positively affected in high PTH animals 
treated with these agents [20] (Figure 5). In high-PTH CKD animals, both vertebra and 
proximal tibia trabecular bone had high bone formation rate, suggesting that simply having 
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high remodeling does not explain the divergent trabecular BV/TV. In conditions where PTH 
is normalized, using calcium supplementation, both trabecular and cortical bone area 
normalized (or enhanced) compared to non-CKD animals. While additional work will be 
necessary to elucidate why long bones and vertebra differentially respond in the setting of 
CKD, it raises concern about the clinical use of iliac crest bone biopsies as an assessment of 
trabecular bone, especially in assessing bone volume [28-32]. It may be that iliac crest 
biopsy changes are more reflective of long bone trabecular responses than they are of the 
vertebra. This is supported by an previous study in renal transplant patients that showed no 
change in iliac crest biopsy cancellous BV/TV after 6 months while spine, but not radius, 
BMD changed significantly during this same time frame [33].
The structural mechanical phenotype of the vertebrae closely follows that of the long bones 
in these same animals, where compromised ultimate load, stiffness, and energy to fracture 
existed in animals with high PTH, even if treated with the potent anti-remodeling agent 
zoledronic acid or the potent anabolic anti-sclerostin antibody [20]. Treatment with calcium, 
to lower PTH, normalized vertebra ultimate load and energy to failure, both parameters that 
have functional significance for fracture resistance [34]. In animals where reduced PTH was 
combined with the anabolic intervention of anti-sclerostin antibody, both ultimate load and 
energy to failure exceeded values from normal animals (Figure 3). Enhanced vertebral 
mechanical properties have similarly been observed in ovariectomized animals treated with 
anti-sclerostin antibody [35]. Yet the response in these CKD animals differs from the long 
bone, where calcium plus anti-sclerostin antibody normalized, but did not significantly 
increase, ultimate load relative to NL animals [20] (Figure 5). These data illustrate the 
importance of normalizing PTH in treating the vertebral mechanical phenotype of CKD and 
highlight that anabolic therapy can be more effective at sites that have large proportions of 
both cortical and trabecular bone (such as the spine and femoral neck).
Structural mechanical properties are determined by bone mass, geometry/architecture, and 
the mechanical properties of the material (sometimes referred to as bone quality) [36]. 
Compromised bone mass and architecture are widely appreciated in CKD while the changes 
in bone quality have only recently begun to be explored [37,38]. We have shown, using both 
calculations of material properties from whole bone tests [11,13,20] as well as by more 
direct measures [9] that long bones of CKD animals have reduced properties at the material 
level. This is associated with changes to both collagen and matrix hydration [39] although a 
cause-effect relationship has not been elucidated. The current work shows that high 
turnover, high PTH CKD disease compromises the mechanical properties of the material – 
as both ultimate stress and toughness, are significantly lower than NL. This means that not 
only does the vertebra have lower bone mass but the bone mass that exists has compromised 
material properties relative to normal. Controlling PTH levels normalizes the material 
properties – contributing to the normalization of whole bone mechanical properties while 
treatments that did not affect PTH (zoledronic acid and anti-sclerostin antibody alone) had 
mixed effects on material properties.
The current experiment utilized zoledronate as a representative bisphosphonate to study in 
the setting of CKD. It is well accepted that each bisphosphonate has different biophysical 
properties of mineral binding strength and affinity to hydroxyapatite [40]. These properties 
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affect many of the physical and physiological actions of the drugs including drug 
localization, speed of onset, degree of remodeling suppression, and speed of withdrawal 
[41]. It is unclear whether a different bisphosphonate would be more beneficial in the setting 
of CKD. Zoledronate has long lasting effects on remodeling suppression, more than 5 years 
following a single dose [42,43] meaning that it would be difficult to washout the effect if 
needed. Lower affinity bisphosphonates, such as risedronate, have been shown to washout 
more rapidly than alendronate (a high affinity agent) [44] suggesting it may be more 
appropriate in the setting of CKD if concerns exist about treatment washout duration. More 
work with bisphosphonates are necessary to understand the details of their effects on bone, 
as well as the safety on the kidney, in the setting of CKD. It is possible that the there is 
diversity in the renal safety among the bisphosphonates but additional work is needed in this 
area [45]. In addition, despite efficacy of calcium in lowering PTH and improving serum 
calcium, in our previous publications we have observed increased arterial calcification 
suggesting that both efficacy and safety should be considered with any interventions.
In conclusion, the present study provides a clear picture of how progressive CKD, with and 
without interventions, affects vertebral bone properties. Since CKD-associated bone disease 
and fracture risk is significant at this site, it is important to recognize that response to 
treatment differs from long bones. Despite these differences, what is clear from this study is 
that reducing PTH is fundamental in normalizing mechanical properties. As such, any anti-
resorptive or anabolic bone therapies utilized in CKD should be examined in combination 
with therapies that suppress PTH (such as calcitriol and 1,25 vitamin D analogs and 
calcimimetics).
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HIGHLIGHTS
- An animal model of progressive kidney disease was studied to understand the 
effects of disease/treatment on spine properties.
- CKD negatively affected cortical and trabecular properties leading to compromised 
mechanical properties.
- Pharmacological treatments were effective in normalizing vertebral structure and 
mechanical properties only if the treatment reduced serum PTH.
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Figure 1. 
Overview of experimental groups, outcome measures, and serum PTH levels for the planned 
comparisons. PTH values from previously published manuscript [20].
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Figure 2. 
Vertebral phenotype of animals with high-PTH CKD compared to normal littermates (NL). 
(A) Trabecular bone formation rate, (B) cortical thickness, (C) trabecular BV/TV, (D) 
ultimate load, and (E) energy to failure. Representative fluorochrome labeling images (taken 
from animal with remodeling values closest to group mean) from vertebral bone of NL (F) 
and CKD (G) animals. Representative 3D reconstructions (taken from the animal with 
BV/TV closest to the group mean) from trabecular bone in the vertebra of NL (H) and CKD 
(I) animals. Representative cross-sections depicting region of cortical thickness assessment 
(in cortex noted by arrow) of NL (J) and CKD (K).# p < 0.05 versus NL.
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Figure 3. 
Influence of reducing remodeling rate, with and without lowering PTH, on the vertebral 
phenotype of animals with CKD. (A) cortical thickness, (B) trabecular BV/TV, (C) ultimate 
load, and (D) energy to failure. Groups with different letters are significantly different (p < 
0.05). For all parameters, the overall ANOVA p value was < 0.05. NL – normal littermates; 
CKD – animals with chronic kidney disease with high PTH levels; CKD-Ca – animals with 
chronic kidney disease treated with calcium to lower remodeling and PTH; CKD-Z – 
animals with chronic kidney disease treated with zoledronic acid to lower remodeling.
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Figure 4. 
Influence of anti-sclerostin antibody treatment, with and without lowering PTH, on the 
vertebral phenotype of animals with CKD. (A) cortical thickness, (B) trabecular BV/TV, (C) 
ultimate load, and (D) energy to failure. Groups with different letters are significantly 
different (p < 0.05). For all parameters, the overall ANOVA p value was < 0.05. NL – 
normal littermates; CKD – animals with chronic kidney disease with high PTH levels; CKD-
Ca – animals with chronic kidney disease treated with calcium to lower remodeling and 
PTH; CKD-SCL – animals with chronic kidney disease treated with anti-sclerostin antibody; 
CKD-SCL-Ca – animals with chronic kidney disease treated with anti-sclerostin antibody 
and calcium (to lower PTPH).
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Figure 5. 
Summary of vertebral and long bone response to disease and treatment response. (A) 
Trabecular bone volume of the vertebra (black bars) and proximal tibia (gray bars). (B) 
Ultimate load of the vertebra (trabecular and cortical bone together; black bars) and the 
femoral diaphysis (purely cortical bone; gray bars). Long bone data were pulled from 
previous publications in this same animal model. Data presented as percent of normal 
animals.
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TABLE 1
Mechanical phenotype of high PTH, high turnover CKD animals
Stiffness, N/mm Ultimate stress, Pa Modulus, Pa Toughness, Pa
NL 1044 ± 250 30.8 ± 3.9 803 ± 208 0.95 ± 0.41
CKD 829 ± 332 23.5 ± 4.2 728 ± 290 0.63 ± 0.17
P value 0.035 0.002 NS 0.04
CKD – Calcium 804 ± 244 37.8 ± 9.9 ab 724 ± 211 b 1.37 ± 0.39 ab
CKD – Zoledronic acid 646 ± 345 23.4 ± 5.2 a 557 ± 279 a 0.86 ± 0.28
ANOVA P value 0.078 0.001 0.001 0.001
CKD-Scl AB 477 ± 237 ab 22.9 ± 5.9 ab 426 ± 200 ab 1.00 ± 0.54 b
CKD-Scl AB + Calcium 1072 ± 503 34.1 ± 8.5 b 709 ± 282 1.23 ± 0.30 b
ANOVA P value 0.002 0.001 0.016 0.006
Data as mean ± SD. Statistical comparisons were conducted as t-test (between NL and CKD), or ANOVA (between NL, CKD, CKD+Calcium, and 
CKD+Zoledronic Acid; and then between NL, CKD, CKD+Calcium, CKD+Scl AB, and CKD+Scl AB+Calcium). Statistically different (p < 0.05) 
values between CKD and NL are given in the t-test p values while differences in the ANOVA are noted relative to NL (a) and CKD (b).
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Table 2
Descriptive characteristics of animal groups.
Final body weight, g Serum calcium, mg/dL Serum phosphorus, mg/dL BUN, mg/dL
NL 554 ± 41 10.3 ± 0.5 4.9 ± 0.9 22 ± 5
CKD 541 ± 36 9.0 ± 2.0 8.4 ± 1.9 49.2 ± 8.2
P value NS NS < 0.001 < 0.001
CKD – Calcium 499 ± 47 ab 11.9 ± 1.5 b 7.0 ± 1.2 ab 61.2 ± 10.5 ab
CKD – Zoledronic acid 531 ± 41 8.7 ± 1.9 7.6 ± 1.9 a 56.2 ± 16.5 ab
ANOVA P value 0.04 < 0.001 < 0.001 < 0.001
CKD-Scl AB 505 ± 57 9.9 ± 2.0 a 9.4 ± 3.9 64.4 ± 11.6 ab
CKD-Scl AB + Ca 515 ± 44 11.1 ± 2.7 a 7.9 ± 2.1 58.4 ± 13.7 ab
ANOVA P value NS 0.018 0.002 < 0.001
Data as mean ± SD. Statistical comparisons were conducted as t-test (between NL and CKD), or ANOVA (between NL, CKD, CKD+Calcium, and 
CKD+Zoledronic Acid; and then between NL, CKD, CKD+Calcium, CKD+Scl AB, and CKD+Scl AB+Calcium). Statistically different (p < 0.05) 
values between CKD and NL are given in the t-test p values while differences in the ANOVA are noted relative to NL (a) and CKD (b).
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